P-21: Research Overview

P-21 (also written P021) is a small synthetic tetrapeptide modeled on the active epitope of ciliary neurotrophic factor (CNTF), a naturally occurring cytokine with neurogenic and neuroprotective properties. The peptide was developed by Khalid Iqbal and colleagues at the New York State Institute for Basic Research in Developmental Disabilities as part of a program to create small-molecule mimetics of neurotrophic factors capable of crossing the blood-brain barrier — a barrier the native CNTF protein cannot efficiently traverse. Preclinical research has examined P-21 primarily in models of Alzheimer's disease, Parkinson's disease, and age-related cognitive decline. No human clinical trials have been registered or completed.

What Is P-21?

P-21 is a four-amino-acid peptide (the sequence is derived from CNTF's most active region via epitope mapping) with an adamantylated glycine appended to its C-terminus to improve lipophilicity and blood-brain barrier penetration and reduce enzymatic degradation. Its molecular weight is approximately 500–600 Da. CNTF itself is a helical cytokine that signals through a receptor complex involving CNTFR-alpha, gp130, and LIFRbeta; the receptor system activates JAK-STAT, MAPK/ERK, and PI3K/Akt pathways. P-21 is a minimized peptidomimetic designed to engage a subset of this signaling apparatus. It is available from research-chemical vendors in lyophilized form and has no regulatory approval for any human use.

Mechanism

P-21's primary reported mechanism involves inhibition of leukemia inhibitory factor (LIF) signaling in the dentate gyrus. LIF, acting through JAK-STAT3, suppresses adult hippocampal neurogenesis; P-21 is proposed to competitively reduce this inhibitory signal, thereby disinhibiting the neurogenic niche. In parallel, P-21 administration in rodent studies is associated with upregulated BDNF expression and enhanced TrkB activation — a downstream pathway that promotes neuronal survival, dendritic arborization, and synaptic density. Increased BDNF, in turn, reduces activity of GSK-3beta (a major tau kinase), offering a proposed explanation for reduced tau hyperphosphorylation observed in Alzheimer's model mice. In this framework, P-21's neurogenic and tau-modulatory effects are linked through a single BDNF-mediated cascade rather than through direct NF-kB modulation, though CNTF-family cytokines do engage NF-kB in some cell contexts.

What the Research Shows

Published research is preclinical only — no human clinical trials have been conducted. A foundational 2010 study by Blanchard et al. (PMID 20952820) in mice reported that chronic dietary P-21 administration increased hippocampal neurogenesis, enhanced synaptic and dendritic complexity, and improved spatial memory in young adult mice — without observed toxicity over a 12-month treatment course. A 2017 study by Kazim et al. (PMID 28655344) in the 3xTg-AD mouse model of Alzheimer's disease found that early P-21 treatment prevented dendritic and synaptic deficits and reversed cognitive impairment, with associated reductions in tau hyperphosphorylation and amyloid-beta burden. Regional comparison studies (PMID 21860085) contrasted P-21's neurogenic effects with cerebrolysin in APP transgenic mice, finding complementary but distinct patterns of neurogenesis promotion. A 2024 PMC study (PMC11590213) examined P-21 in a CDKL5 deficiency disorder model, extending the research into rare neurodevelopmental disease. Across studies, chronic oral dosing at 60 nmol/g diet was reported to be well-tolerated with no adverse effects on body weight, organ histology, or hematological parameters in rodents.

The published literature on P-21 spans approximately 15 peer-reviewed studies from 2010 to 2025, concentrated in the Iqbal laboratory and collaborators. Independent replication outside this group is limited. No pharmacokinetic studies in humans have been published, and no IND (Investigational New Drug) application or equivalent has been publicly filed for P-21 as of 2026.

Reported Research Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Preclinical rodent doses cannot be directly translated to humans; published human dose-finding studies do not exist. Published rodent studies have used P-21 primarily as a dietary supplement mixed into chow at a concentration of 60 nmol per gram of diet, delivered chronically over weeks to months. Some studies have used subcutaneous or intranasal administration without specifying standardized weight-based quantities readily comparable across methods. No human pharmacokinetic, safety, or tolerability studies have been published. Conversion of rodent dietary doses to a human equivalent requires allometric scaling and assumptions that have not been validated for this compound.

References

1. Blanchard J et al. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. 2010;21(4):1185-1195. PMID 20952820.

2. Kazim SF et al. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound in Alzheimer's disease. Sci Rep. 2017;7(1):4559. PMID 28655344.

3. Bolognin S et al. Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice. J Alzheimers Dis. 2011;25(4):625-634. PMID 21860085.

4. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. PubMed 2024. PMID 39592934. PMC 11590213.